1
|
Zhang X, Su W, Guo H, Fang P, Yang K, Song Q. N-Heterocycle-Editing to Access Fused-BN-Heterocycles via Ring-Opening/C-H Borylation/Reductive C-B Bond Formation. Angew Chem Int Ed Engl 2024; 63:e202318613. [PMID: 38196396 DOI: 10.1002/anie.202318613] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2023] [Revised: 01/09/2024] [Accepted: 01/10/2024] [Indexed: 01/11/2024]
Abstract
Skeletal editing of N-heterocycles has recently received considerable attention, and the introduction of boron atom into heterocycles often results in positive property changes. However, direct enlargement of N-heterocycles through boron atom insertion is rarely reported in the literature. Here, we report a N-heterocyclic editing reaction through the combination boron atom insertion and C-H borylation, accessing the fused-BN-heterocycles. The synthetic potential of this chemistry was demonstrated by substrate scope and late-stage diversification of products.
Collapse
Affiliation(s)
- Xu Zhang
- Key Laboratory of Molecule Synthesis and Function Discovery, Fujian Province University, College of Chemistry at Fuzhou University, Fuzhou, Fujian, 350108, China
| | - Wanlan Su
- Key Laboratory of Molecule Synthesis and Function Discovery, Fujian Province University, College of Chemistry at Fuzhou University, Fuzhou, Fujian, 350108, China
| | - Huosheng Guo
- Key Laboratory of Molecule Synthesis and Function Discovery, Fujian Province University, College of Chemistry at Fuzhou University, Fuzhou, Fujian, 350108, China
| | - Pengyuan Fang
- Key Laboratory of Molecule Synthesis and Function Discovery, Fujian Province University, College of Chemistry at Fuzhou University, Fuzhou, Fujian, 350108, China
| | - Kai Yang
- Key Laboratory of Molecule Synthesis and Function Discovery, Fujian Province University, College of Chemistry at Fuzhou University, Fuzhou, Fujian, 350108, China
| | - Qiuling Song
- Key Laboratory of Molecule Synthesis and Function Discovery, Fujian Province University, College of Chemistry at Fuzhou University, Fuzhou, Fujian, 350108, China
- School of Chemistry and Chemical Engineering, Henan Normal University, Xinxiang, Henan, 453007, China
| |
Collapse
|
2
|
Cai T, Zhang Z, Li P, Sun T, Chen X, Ni Y, Chen J, Xu H, Xu Y, Wu C, Shen R, Gao Y. Radical Cascade Bicyclization/Aromatization of 1,7‐Enynes with 1,3‐Dicarbonyl Compounds towards 2,3‐Dihydro‐1
H
‐cyclopenta[
a
]naphthalenes. Adv Synth Catal 2021. [DOI: 10.1002/adsc.202100678] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Affiliation(s)
- Tao Cai
- College of Chemistry and Chemical Engineering Shaoxing University Shaoxing 312000 People's Republic of China
- Zhejiang Engineering Research Center of Fat-Soluble Vitamin Shaoxing 312000 People's Republic of China
| | - Zhebing Zhang
- College of Chemistry and Chemical Engineering Shaoxing University Shaoxing 312000 People's Republic of China
| | - Peiqin Li
- College of Chemistry and Chemical Engineering Shaoxing University Shaoxing 312000 People's Republic of China
| | - Tao Sun
- College of Chemistry and Chemical Engineering Shaoxing University Shaoxing 312000 People's Republic of China
| | - Xinyu Chen
- College of Chemistry and Chemical Engineering Shaoxing University Shaoxing 312000 People's Republic of China
| | - Yuqi Ni
- College of Chemistry and Chemical Engineering Shaoxing University Shaoxing 312000 People's Republic of China
| | - Jianhui Chen
- College of Chemistry and Chemical Engineering Shaoxing University Shaoxing 312000 People's Republic of China
- Zhejiang Engineering Research Center of Fat-Soluble Vitamin Shaoxing 312000 People's Republic of China
| | - Huiting Xu
- College of Chemistry and Chemical Engineering Shaoxing University Shaoxing 312000 People's Republic of China
- Zhejiang Engineering Research Center of Fat-Soluble Vitamin Shaoxing 312000 People's Republic of China
| | - Yanfei Xu
- College of Chemistry and Chemical Engineering Shaoxing University Shaoxing 312000 People's Republic of China
- Zhejiang Engineering Research Center of Fat-Soluble Vitamin Shaoxing 312000 People's Republic of China
| | - Chunlei Wu
- College of Chemistry and Chemical Engineering Shaoxing University Shaoxing 312000 People's Republic of China
- Zhejiang Engineering Research Center of Fat-Soluble Vitamin Shaoxing 312000 People's Republic of China
| | - Runpu Shen
- College of Chemistry and Chemical Engineering Shaoxing University Shaoxing 312000 People's Republic of China
- Zhejiang Engineering Research Center of Fat-Soluble Vitamin Shaoxing 312000 People's Republic of China
| | - Yuzhen Gao
- Key Laboratory of Coal to Ethylene Glycol and Its Related Technology Fujian Institute of Research on the Structure of Matter Chinese Academy of Sciences Fuzhou Fujian 350002 People's Republic of China
| |
Collapse
|
3
|
Ali KA, Ragab EA, Mlostoń G, Celeda M, Linden A, Heimgartner H. Unexpected Reaction Course of 3-Amino-5-aryl-1H-pyrazoles with Dialkyl Dicyanofumarates. Helv Chim Acta 2013. [DOI: 10.1002/hlca.201200633] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
4
|
Yulyaningsih E, Zhang L, Herzog H, Sainsbury A. NPY receptors as potential targets for anti-obesity drug development. Br J Pharmacol 2011; 163:1170-202. [PMID: 21545413 DOI: 10.1111/j.1476-5381.2011.01363.x] [Citation(s) in RCA: 102] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
The neuropeptide Y system has proven to be one of the most important regulators of feeding behaviour and energy homeostasis, thus presenting great potential as a therapeutic target for the treatment of disorders such as obesity and at the other extreme, anorexia. Due to the initial lack of pharmacological tools that are active in vivo, functions of the different Y receptors have been mainly studied in knockout and transgenic mouse models. However, over recent years various Y receptor selective peptidic and non-peptidic agonists and antagonists have been developed and tested. Their therapeutic potential in relation to treating obesity and other disorders of energy homeostasis is discussed in this review.
Collapse
Affiliation(s)
- Ernie Yulyaningsih
- Neuroscience Research Program, Garvan Institute of Medical Research, St Vincent's Hospital, Darlinghurst, Sydney, NSW, Australia
| | | | | | | |
Collapse
|
5
|
Huang X, Zhang T. Cascade nucleophilic addition-cyclic Michael addition of arynes and phenols/anilines bearing ortho alpha,beta-unsaturated groups: facile synthesis of 9-functionalized xanthenes/acridines. J Org Chem 2010; 75:506-9. [PMID: 20020766 DOI: 10.1021/jo902311a] [Citation(s) in RCA: 59] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
A facile synthesis of xanthenes and acridines based on a cascade nucleophilic addition-cyclic Michael addition process of arynes and phenols/anilines substituted with alpha,beta-unsaturated groups at the ortho positions is described. The reaction has also been successfully extended to the synthesis of 9-spiro-xanthene and acridine derivatives with potential biochemical interest.
Collapse
Affiliation(s)
- Xian Huang
- Department of Chemistry, Zhejiang University (Xixi Campus), Hangzhou 310028, People's Republic of China.
| | | |
Collapse
|
6
|
Takahashi H, Haga Y, Shibata T, Nonoshita K, Sakamoto T, Moriya M, Ohe T, Chiba M, Mitobe Y, Kitazawa H, Iwaasa H, Ishihara A, Ishii Y, Kanatani A, Fukami T. Identification of positron emission tomography ligands for NPY Y5 receptors in the brain. Bioorg Med Chem Lett 2009; 19:5436-9. [DOI: 10.1016/j.bmcl.2009.07.103] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2009] [Revised: 07/21/2009] [Accepted: 07/22/2009] [Indexed: 12/01/2022]
|
7
|
Discovery of trans-N-[1-(2-fluorophenyl)-3-pyrazolyl]-3-oxospiro[6-azaisobenzofuran-1(3H),1'-cyclohexane]-4'-carboxamide, a potent and orally active neuropeptide Y Y5 receptor antagonist. Bioorg Med Chem 2009; 17:6971-82. [PMID: 19720539 DOI: 10.1016/j.bmc.2009.08.019] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2009] [Revised: 08/05/2009] [Accepted: 08/05/2009] [Indexed: 11/23/2022]
Abstract
A series of trans-3-oxospiro[(aza)isobenzofuran-1(3H),1'-cyclohexane]-4'-carboxamide derivatives were synthesized to identify potent NPY Y5 receptor antagonists. Of the compounds, 21j showed high Y5 binding affinity, metabolic stability and brain and cerebrospinal fluid (CSF) penetration, and low susceptibility to P-glycoprotein transporters. Oral administration of 21j significantly inhibited the Y5 agonist-induced food intake in rats with a minimum effective dose of 1mg/kg. This compound was selected for proof-of-concept studies in human clinical trials.
Collapse
|
8
|
Ando M, Sato N, Nagase T, Nagai K, Ishikawa S, Takahashi H, Ohtake N, Ito J, Hirayama M, Mitobe Y, Iwaasa H, Gomori A, Matsushita H, Tadano K, Fujino N, Tanaka S, Ohe T, Ishihara A, Kanatani A, Fukami T. Discovery of pyridone-containing imidazolines as potent and selective inhibitors of neuropeptide Y Y5 receptor. Bioorg Med Chem 2009; 17:6106-22. [DOI: 10.1016/j.bmc.2009.05.069] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2009] [Revised: 05/27/2009] [Accepted: 05/28/2009] [Indexed: 11/16/2022]
|
9
|
Sakamoto T, Moriya M, Tsuge H, Takahashi T, Haga Y, Nonoshita K, Okamoto O, Takahashi H, Sakuraba A, Hirohashi T, Shibata T, Kanno T, Ito J, Iwaasa H, Gomori A, Ishihara A, Fukuroda T, Kanatani A, Fukami T. Novel orally active NPY Y5 receptor antagonists: Synthesis and structure-activity relationship of spiroindoline class compounds. Bioorg Med Chem 2009; 17:5015-26. [PMID: 19525116 DOI: 10.1016/j.bmc.2009.05.064] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2009] [Revised: 05/25/2009] [Accepted: 05/27/2009] [Indexed: 10/20/2022]
Abstract
Spiroindoline urea derivatives, designed to act as NPY Y5 receptor antagonists, were synthesized and their structure-activity relationships were investigated. Of these derivatives, compound 3a showed good Y5 binding affinity with favorable pharmacokinetic properties. Compound 3a significantly inhibited bPP Y5 agonist-induced food intake in rats, and suppressed body weight gain in DIO mice.
Collapse
Affiliation(s)
- Toshihiro Sakamoto
- Tsukuba Research Institute, Merck Research Laboratories, Banyu Pharmaceutical Co., Ltd, Okubo-3, Tsukuba, Ibaraki 300-2611, Japan.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Development of Non-peptidic Farnesyltransferase Inhibitors based on the Ca1a2of Ras-CaaX. B KOREAN CHEM SOC 2009. [DOI: 10.5012/bkcs.2009.30.2.291] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
11
|
Sakamoto T, Moriya M, Haga Y, Takahashi T, Shibata T, Okamoto O, Nonoshita K, Kitazawa H, Hidaka M, Gomori A, Iwaasa H, Ishihara A, Kanatani A, Fukami T, Gao YD, Macneil DJ, Yang L. Identification of novel and orally active spiroindoline NPY Y5 receptor antagonists. Bioorg Med Chem Lett 2009; 19:1564-8. [PMID: 19243937 DOI: 10.1016/j.bmcl.2009.02.035] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2009] [Revised: 02/04/2009] [Accepted: 02/07/2009] [Indexed: 11/24/2022]
Abstract
A series of spiroindoline-3,4'-piperidine derivatives were synthesized and evaluated for their binding affinities and antagonistic activities at Y5 receptors. Potent Y5 antagonists were tested for their oral bioavailabilities and brain penetration in rats. Some of the antagonists showed good oral bioavailability and/or good brain penetration. In particular, compound 6e was orally bioavailable and brain penetrant, and oral administration of 6e inhibited bPP-induced food intake in rats with a minimum effective dose of 10mg/kg.
Collapse
Affiliation(s)
- Toshihiro Sakamoto
- Tsukuba Research Institute, Banyu Pharmaceutical Co., Ltd, Okubo 3, Tsukuba 300-2611, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Sato N, Jitsuoka M, Ishikawa S, Nagai K, Tsuge H, Ando M, Okamoto O, Iwaasa H, Gomori A, Ishihara A, Kanatani A, Fukami T. Discovery of substituted 2,4,4-triarylimidazoline derivatives as potent and selective neuropeptide Y Y5 receptor antagonists. Bioorg Med Chem Lett 2009; 19:1670-4. [PMID: 19233647 DOI: 10.1016/j.bmcl.2009.01.101] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2008] [Revised: 01/28/2009] [Accepted: 01/30/2009] [Indexed: 11/18/2022]
Abstract
Novel imidazoline derivatives were discovered to be potent neuropeptide Y Y5 receptor antagonists. High-throughput screening of Merck sample collections against the human Y5 receptor resulted in the identification of 2,4,4-triphenylimidazoline (1), which had an IC(50) of 54nM. Subsequent optimization led to the identification of several potent derivatives.
Collapse
Affiliation(s)
- Nagaaki Sato
- Tsukuba Research Institute, Merck Research Laboratories, Banyu Pharmaceutical Company, Ltd, 3 Okubo, Tsukuba 300-2611, Japan
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Ogino Y, Ohtake N, Nagae Y, Matsuda K, Moriya M, Suga T, Ishikawa M, Kanesaka M, Mitobe Y, Ito J, Kanno T, Ishihara A, Iwaasa H, Ohe T, Kanatani A, Fukami T. Design, syntheses, and structure–activity relationships of novel NPY Y5 receptor antagonists: 2-{3-Oxospiro[isobenzofuran-1(3H),4′-piperidin]-1′-yl}benzimidazole derivatives. Bioorg Med Chem Lett 2008; 18:5010-4. [DOI: 10.1016/j.bmcl.2008.08.018] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2008] [Revised: 07/15/2008] [Accepted: 08/06/2008] [Indexed: 10/21/2022]
|
14
|
Ogino Y, Ohtake N, Nagae Y, Matsuda K, Ishikawa M, Moriya M, Kanesaka M, Mitobe Y, Ito J, Kanno T, Ishihara A, Iwaasa H, Ohe T, Kanatani A, Fukami T. Syntheses and structure-activity relationships of novel, potent, and selective trans-2-[3-oxospiro[isobenzofuran-1(3H),1'-cyclohexan]-4'-yl]benzimidazole NPY Y5 receptor antagonists. Bioorg Med Chem Lett 2008; 18:4997-5001. [PMID: 18752943 DOI: 10.1016/j.bmcl.2008.08.021] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2008] [Revised: 07/31/2008] [Accepted: 08/08/2008] [Indexed: 11/28/2022]
Abstract
Syntheses and structure-activity relationships of a novel class of 2-[3-oxospiro[isobenzofuran-1(3H),1'-cyclohexan]-4'-yl]benzimidazole NPY Y5 receptor antagonists are described. Optimization of the lead compound 2a by incorporating substituents into the 5-position or into both the 5- and 6-positions of the benzimidazole core part led to the identification of 5-(5-methyl-1,2,4-oxadiazol-2-yl)benzimidazole (2r: IC(50)=3.3 nM) and 5-(2-methyltetrazol-5-yl)benzimidazole (2u: IC(50)=5.9 nM), both of which are potent, selective, and orally bioavailable Y5 receptor antagonists.
Collapse
Affiliation(s)
- Yoshio Ogino
- Banyu Tsukuba Research Institute, Banyu Pharmaceutical Co. Ltd, Okubo-3, Tsukuba 300-2611, Ibaraki, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Sato N, Jitsuoka M, Shibata T, Hirohashi T, Nonoshita K, Moriya M, Haga Y, Sakuraba A, Ando M, Ohe T, Iwaasa H, Gomori A, Ishihara A, Kanatani A, Fukami T. (9S)-9-(2-hydroxy-4,4-dimethyl-6-oxo-1-cyclohexen-1-yl)-3,3-dimethyl-2,3,4,9-tetrahydro-1H-xanthen-1-one, a selective and orally active neuropeptide Y Y5 receptor antagonist. J Med Chem 2008; 51:4765-70. [PMID: 18637668 DOI: 10.1021/jm8003587] [Citation(s) in RCA: 46] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
(9S)-9-(2-Hydroxy-4,4-dimethyl-6-oxo-1-cyclohexen-1-yl)-3,3-dimethyl-2,3,4,9-tetrahydro-1H-xanthen-1-one ((S)-1) was identified as a selective and orally active neuropeptide Y Y5 receptor antagonist. The structure-activity relationship for this structural class was investigated and showed that limited substitution on the phenyl ring was tolerated and that modification of the 4,4-dimethyl group of the cyclohexenone and the 3,3-dimethyl group of the xanthenone parts slightly improved potency. The plasma concentration-time profile after oral administration of (S)-1 in Sprague-Dawley (SD) rats showed significant in vivo racemization of (S)-1 and that (S)-1 is cleared much more quickly than (R)-1. The duration of (S)-1 in SD rats after oral administration of (RS)-1 racemate was twice as long as that following oral administration of (S)-1. The C max values of (S)-1 after administration of (S)-1 and (RS)-1 were comparable, and the brain to plasma ratio for (S)-1 was 0.34 in SD rats. In our acute D-Trp (34)NPY-induced food intake model, both (S)-1 and (RS)-1 showed potent and dose-dependent efficacy. Therefore, the use of (RS)-1 is suitable for studies that require sustained plasma exposure of (S)-1.
Collapse
Affiliation(s)
- Nagaaki Sato
- Tsukuba Research Institute, Merck Research Laboratories, Banyu Pharmaceutical Co, Ltd, Okubo 3, Tsukuba 300-2611, Japan.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Abstract
Obesity is a serious public health problem throughout the world, affecting both developed societies and developing countries. The central nervous system has developed a meticulously interconnected circuitry in order to keep us fed and in an adequate nutritional state. One of these consequences is that an energy-dense environment favors the development of obesity. Neuropeptide Y (NPY) is one of the most abundant and widely distributed peptides in the central nervous system of both rodents and humans and has been implicated in a variety of physiological actions. Within the hypothalamus, NPY plays an essential role in the control of food intake and body weight. Centrally administered NPY causes robust increases in food intake and body weight and, with chronic administration, can eventually produce obesity. NPY activates a population of at least six G protein-coupled Y receptors. NPY analogs exhibit varying degrees of affinity and specificity for these Y receptors. There has been renewed speculation that ligands for Y receptors may be of benefit for the treatment of obesity. This review highlights the therapeutic potential of Y(1), Y(2), Y(4), and Y(5) receptor agonists and antagonists as additional intervention to treat human obesity.
Collapse
Affiliation(s)
- M M Kamiji
- Department of Gastroenterology, Faculty of Medicine, University of Sao Paulo, Ribeirão Preto Campus 14048-900, Ribeirão Preto-SP, Brazil
| | | |
Collapse
|
17
|
Erondu N, Addy C, Lu K, Mallick M, Musser B, Gantz I, Proietto J, Astrup A, Toubro S, Rissannen AM, Tonstad S, Haynes WG, Gottesdiener KM, Kaufman KD, Amatruda JM, Heymsfield SB. NPY5R antagonism does not augment the weight loss efficacy of orlistat or sibutramine. Obesity (Silver Spring) 2007; 15:2027-42. [PMID: 17712121 DOI: 10.1038/oby.2007.242] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
OBJECTIVE Central counter-regulatory mechanisms, including those related to the orexigenic hormone neuropeptide Y (NPY), may limit the weight loss observed with conventional pharmacological monotherapy. This study evaluated whether blockade of the NPY Y5 receptor (NPY5R) with the selective antagonist MK-0557 potentiates sibutramine and orlistat weight loss effects. RESEARCH METHODS AND PROCEDURES Obese patients (497, BMI 30 to 43 kg/m2) were randomized to 1 of 5 treatment arms [placebo, n = 101; sibutramine 10 mg/d, n = 100; MK-0557 1 mg/d plus sibutramine 10 mg/d, n = 98; orlistat 120 mg TID, n = 99; MK-0557 1 mg/d plus orlistat 120 mg TID, n = 99] in conjunction with a hypocaloric diet for 24 weeks. The all-patients-treated population, imputing missing data using last observation carried forward, was used to assess weight loss from baseline. RESULTS The study was completed by 71% of patients in placebo, 76% in sibutramine alone, 79% in MK-0557 + sibutramine, 69% in orlistat alone, and 76% in MK-0557 + orlistat groups. Least squares (LS) mean difference [95% confidence interval (CI)] in weight change from baseline between MK-0557 + sibutramine and sibutramine alone was -0.1 (-1.6, 1.4) kg (p = 0.892) and between MK-0557 + orlistat and orlistat alone was -0.9 (-2.4, 0.6) kg (p = 0.250). Sibutramine alone induced a LS mean weight loss of -5.9 (-6.9, -4.9) kg vs. -4.6 (-5.7, -3.6) kg for orlistat (p = 0.097). There were no serious drug-related adverse events and MK-0557 was well tolerated. DISCUSSION Blockade of the NPY5R with the potent antagonist MK-0557 did not significantly increase the weight loss efficacy of either orlistat or sibutramine monotherapy.
Collapse
Affiliation(s)
- Ngozi Erondu
- Merck Research Laboratories, 126 E. Lincoln Avenue, PO Box 2000, RY34A-Rahway, NJ 07065-0900, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Blakeney JS, Reid RC, Le GT, Fairlie DP. Nonpeptidic Ligands for Peptide-Activated G Protein-Coupled Receptors. Chem Rev 2007; 107:2960-3041. [PMID: 17622179 DOI: 10.1021/cr050984g] [Citation(s) in RCA: 78] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Jade S Blakeney
- Centre for Drug Design and Development, Institute for Molecular Bioscience, University of Queensland, Brisbane, Queensland 4072, Australia
| | | | | | | |
Collapse
|
19
|
Takahashi T, Sakuraba A, Hirohashi T, Shibata T, Hirose M, Haga Y, Nonoshita K, Kanno T, Ito J, Iwaasa H, Kanatani A, Fukami T, Sato N. Novel potent neuropeptide Y Y5 receptor antagonists: Synthesis and structure–activity relationships of phenylpiperazine derivatives. Bioorg Med Chem 2006; 14:7501-11. [PMID: 16919461 DOI: 10.1016/j.bmc.2006.07.023] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2006] [Accepted: 07/07/2006] [Indexed: 11/20/2022]
Abstract
A series of phenylpiperazine derivatives were synthesized and evaluated for their neuropeptide Y (NPY) Y5 receptor antagonistic activities. The benzindane portion of 2 was replaced by 1-phenylpiperazine, resulting in novel urea derivative 3f. Subsequent optimization of the phenylpiperazine template by substitution of the phenyl moiety resulted in a series of (2-methanesulfonamidephenyl)piperazine derivatives that showed potent binding affinity and antagonistic activity for the Y5 receptor.
Collapse
Affiliation(s)
- Toshiyuki Takahashi
- Tsukuba Research Institute, Banyu Pharmaceutical Co., Ltd, Okubo 3, Tsukuba 300-2611, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Ishihara A, Kanatani A, Mashiko S, Tanaka T, Hidaka M, Gomori A, Iwaasa H, Murai N, Egashira SI, Murai T, Mitobe Y, Matsushita H, Okamoto O, Sato N, Jitsuoka M, Fukuroda T, Ohe T, Guan X, MacNeil DJ, Van der Ploeg LHT, Nishikibe M, Ishii Y, Ihara M, Fukami T. A neuropeptide Y Y5 antagonist selectively ameliorates body weight gain and associated parameters in diet-induced obese mice. Proc Natl Acad Sci U S A 2006; 103:7154-8. [PMID: 16636293 PMCID: PMC1459032 DOI: 10.1073/pnas.0510320103] [Citation(s) in RCA: 66] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023] Open
Abstract
Neuropeptide Y (NPY) is thought to have a major role in the physiological control of energy homeostasis. Among five NPY receptors described, the NPY Y5 receptor (Y5R) is a prime candidate to mediate some of the effects of NPY on energy homeostasis, although its role in physiologically relevant rodent obesity models remains poorly defined. We examined the effect of a potent and highly selective Y5R antagonist in rodent obesity and dietary models. The Y5R antagonist selectively ameliorated diet-induced obesity (DIO) in rodents by suppressing body weight gain and adiposity while improving the DIO-associated hyperinsulinemia. The compound did not affect the body weight of lean mice fed a regular diet or genetically obese leptin receptor-deficient mice or rats, despite similarly high brain Y5R receptor occupancy. The Y5R antagonist acts in a mechanism-based manner, as the compound did not affect DIO of Y5R-deficient mice. These results indicate that Y5R is involved in the regulation and development of DIO and suggest utility for Y5R antagonists in the treatment of obesity.
Collapse
Affiliation(s)
- Akane Ishihara
- *Tsukuba Research Institute, Banyu Pharmaceutical Co., Ltd., 3 Okubo, Tsukuba 300-2611, Japan
- To whom correspondence may be addressed. E-mail:
akane@ or akio@
| | - Akio Kanatani
- *Tsukuba Research Institute, Banyu Pharmaceutical Co., Ltd., 3 Okubo, Tsukuba 300-2611, Japan
- To whom correspondence may be addressed. E-mail:
akane@ or akio@
| | - Satoshi Mashiko
- *Tsukuba Research Institute, Banyu Pharmaceutical Co., Ltd., 3 Okubo, Tsukuba 300-2611, Japan
| | - Takeshi Tanaka
- *Tsukuba Research Institute, Banyu Pharmaceutical Co., Ltd., 3 Okubo, Tsukuba 300-2611, Japan
| | - Masayasu Hidaka
- *Tsukuba Research Institute, Banyu Pharmaceutical Co., Ltd., 3 Okubo, Tsukuba 300-2611, Japan
| | - Akira Gomori
- *Tsukuba Research Institute, Banyu Pharmaceutical Co., Ltd., 3 Okubo, Tsukuba 300-2611, Japan
| | - Hisashi Iwaasa
- *Tsukuba Research Institute, Banyu Pharmaceutical Co., Ltd., 3 Okubo, Tsukuba 300-2611, Japan
| | - Naomi Murai
- *Tsukuba Research Institute, Banyu Pharmaceutical Co., Ltd., 3 Okubo, Tsukuba 300-2611, Japan
| | - Shin-ichiro Egashira
- *Tsukuba Research Institute, Banyu Pharmaceutical Co., Ltd., 3 Okubo, Tsukuba 300-2611, Japan
| | - Takashi Murai
- *Tsukuba Research Institute, Banyu Pharmaceutical Co., Ltd., 3 Okubo, Tsukuba 300-2611, Japan
| | - Yuko Mitobe
- *Tsukuba Research Institute, Banyu Pharmaceutical Co., Ltd., 3 Okubo, Tsukuba 300-2611, Japan
| | - Hiroko Matsushita
- *Tsukuba Research Institute, Banyu Pharmaceutical Co., Ltd., 3 Okubo, Tsukuba 300-2611, Japan
| | - Osamu Okamoto
- *Tsukuba Research Institute, Banyu Pharmaceutical Co., Ltd., 3 Okubo, Tsukuba 300-2611, Japan
| | - Nagaaki Sato
- *Tsukuba Research Institute, Banyu Pharmaceutical Co., Ltd., 3 Okubo, Tsukuba 300-2611, Japan
| | - Makoto Jitsuoka
- *Tsukuba Research Institute, Banyu Pharmaceutical Co., Ltd., 3 Okubo, Tsukuba 300-2611, Japan
| | - Takahiro Fukuroda
- *Tsukuba Research Institute, Banyu Pharmaceutical Co., Ltd., 3 Okubo, Tsukuba 300-2611, Japan
| | - Tomoyuki Ohe
- *Tsukuba Research Institute, Banyu Pharmaceutical Co., Ltd., 3 Okubo, Tsukuba 300-2611, Japan
| | | | | | | | - Masaru Nishikibe
- *Tsukuba Research Institute, Banyu Pharmaceutical Co., Ltd., 3 Okubo, Tsukuba 300-2611, Japan
| | - Yasuyuki Ishii
- *Tsukuba Research Institute, Banyu Pharmaceutical Co., Ltd., 3 Okubo, Tsukuba 300-2611, Japan
| | - Masaki Ihara
- *Tsukuba Research Institute, Banyu Pharmaceutical Co., Ltd., 3 Okubo, Tsukuba 300-2611, Japan
| | - Takehiro Fukami
- *Tsukuba Research Institute, Banyu Pharmaceutical Co., Ltd., 3 Okubo, Tsukuba 300-2611, Japan
| |
Collapse
|
21
|
Kanatani A, Ishihara A, Iwaasa H, MacNeil DJ, Fukami T. [Development of anorectic NPY antagonists: possible roles of Y1 and Y5 receptors in feeding regulation]. Nihon Yakurigaku Zasshi 2006; 127:88-91. [PMID: 16595978 DOI: 10.1254/fpj.127.88] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/08/2023]
|
22
|
MacNeil DJ, Kanatani A. NPY and energy homeostasis: an opportunity for novel anti-obesity therapies. EXS 2006:143-56. [PMID: 16383004 DOI: 10.1007/3-7643-7417-9_11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/05/2023]
Affiliation(s)
- Douglas J MacNeil
- Metabolic Disorders, Merck Research Laboratories, Rahway, NJ 07090, USA.
| | | |
Collapse
|
23
|
Iida T, Satoh H, Maeda K, Yamamoto Y, Asakawa KI, Sawada N, Wada T, Kadowaki C, Itoh T, Mase T, Weissman SA, Tschaen D, Krska S, Volante RP. Practical Synthesis of a Neuropeptide Y Antagonist via Stereoselective Addition to a Ketene. J Org Chem 2005; 70:9222-9. [PMID: 16268594 DOI: 10.1021/jo0512709] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
[Reaction: see text]. The synthesis of neuropeptide Y antagonist 1, currently under clinical investigation for the treatment of obesity, is described. The convergent synthesis from trans-spirolactone carboxylic acid intermediate 2a and aminopyrazole 3 is predicated on a stereoselective route to the former. The coupling reaction of ethyl 4-oxocyclohexanecarboxylate (10a) with lithiated isonicotinamide 11 was investigated in detail, but even optimized conditions only provided a 45:55 ratio of trans:cis isomers (12a:12b). While selective crystallization schemes were developed to isolate the thermodynamically less stable trans isomer 2a, improved stereocontrol was subsequentially achieved by the application of ketene chemistry. The ketene formation and quench was investigated under a variety of conditions aimed at maximizing the trans:cis ratio. Reacting a mixture of carboxylic acids 2a and 2b with POCl3 in THF, followed by concomitant addition of tert-butyl alcohol in the presence of TMEDA at 35 degrees C provided a 4:1 ratio of trans:cis tert-butyl esters (18a:18b) via in situ ketene formation. Ester hydrolysis, followed by selective crystallization of undesired 2b as the HCl salt, led to isolation of 2a in 47% overall yield. Aminopyrazole intermediate 3 was synthesized via the condensation reaction of 2-fluorophenylhydrazine hydrochloride (4a) with acrylonitrile derivative 5 in 65-70% yield. Coupling of advanced intermediates 2a and 3b via activation with thionyl chloride gave a 92% yield of 1.
Collapse
Affiliation(s)
- Takehiko Iida
- Process Research, Process R&D, Laboratories for Technology Development, Banyu Pharmaceutical Co., Ltd., 9-1 Kamimutsuna 3-chome, Okazaki, Aichi 444-0858 Japan.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Luo G, Mattson GK, Bruce MA, Wong H, Murphy BJ, Longhi D, Antal-Zimanyi I, Poindexter GS. Isosteric N-arylpiperazine replacements in a series of dihydropyridine NPY1 receptor antagonists. Bioorg Med Chem Lett 2005; 14:5975-8. [PMID: 15546711 DOI: 10.1016/j.bmcl.2004.10.005] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2002] [Revised: 09/28/2004] [Accepted: 10/02/2004] [Indexed: 10/26/2022]
Abstract
4-Amino-N-arylpiperidines serve as effective bioisosteres for N-arylpiperazines in the series of dihydropyridine NPY1 receptor antagonists. These were prepared by a ZnCl2-mediated reductive amination reaction between elaborated primary amines, 2 or 5, and 4-arylpiperidones.
Collapse
Affiliation(s)
- Guanglin Luo
- Bristol-Myers Squibb Pharmaceutical Research Institute, Department of Chemistry, 5 Research Parkway, Wallingford, CT, USA.
| | | | | | | | | | | | | | | |
Collapse
|
25
|
Blum CA, Zheng X, De Lombaert S. Design, synthesis, and biological evaluation of substituted 2-cyclohexyl-4-phenyl-1H-imidazoles: potent and selective neuropeptide Y Y5-receptor antagonists. J Med Chem 2004; 47:2318-25. [PMID: 15084130 DOI: 10.1021/jm030490g] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Antagonizing the robust stimulation of food intake by neuropeptide Y represents a new potential therapeutic approach for the treatment of obesity. Earlier pharmacological studies have pointed to the Y1 and Y5 receptors as the most likely mediators of the NPY orexigenic response. In this paper, we describe a new series of small molecule Y5 antagonists derived from a 2,4-diaryl-1H-imidazole lead. The main objectives of our structural optimization efforts were to produce novel and potent Y5 antagonists with an improved oral pharmacokinetic profile and less affinity for the hERG potassium channel compared to the lead 2,4-diarylimidazole structures. These goals were accomplished by replacement of the 2-aryl ring with a cyclohexyl ring and subsequent elaboration of the 4-position of the cyclohexyl ring with a variety of hydrophilic functionalities. The resulting compound, N-(2-hydroxy-tert-butyl)(4-[4-[3-(trifluoromethyl)phenyl]imidazol-2-yl]cyclohexyl)carboxamide (20), displayed good potency at the Y5 receptor (K(i) = 3 nM), while interactions at the hERG channel were essentially eliminated (6% inhibition at a concentration of 3 microM). Importantly, the pharmacokinetic properties of 20 (F = 36%) represented a marked improvement over that of the initial 2,4-diarylimidazole structures.
Collapse
Affiliation(s)
- Charles A Blum
- Neurogen Corporation, 35 Northeast Industrial Road, Branford, Connecticut 06405, USA.
| | | | | |
Collapse
|
26
|
Rueeger H, Gerspacher M, Buehlmayer P, Rigollier P, Yamaguchi Y, Schmidlin T, Whitebread S, Nuesslein-Hildesheim B, Nick H, Cricione L. Discovery and SAR of potent, orally available and brain-penetrable 5,6-dihydro-4H-3-thia-1-aza-benzo[e]azulen- and 4,5-dihydro-6-oxa-3-thia-1-aza-benzo[e]azulen derivatives as neuropeptide Y Y5 receptor antagonists. Bioorg Med Chem Lett 2004; 14:2451-7. [PMID: 15109631 DOI: 10.1016/j.bmcl.2004.03.014] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2003] [Revised: 02/11/2004] [Accepted: 03/04/2004] [Indexed: 10/26/2022]
Abstract
Combination of structural elements from a potent Y5 antagonist (2) with thiazole fragments that exhibit weak Y5 affinities followed by lead optimisation led to the discovery of (5,6-dihydro-4H-3-thia-1-aza-benzo[e]azulen-2-yl)-piperidin-4-ylmethyl-amino and (4,5-dihydro-6-oxa-3-thia-1-aza-benzo[e]azulen-2-yl)-piperidin-4-ylmethyl-amino derivatives. Both classes of compounds are capable of delivering potent and selective orally and centrally bioavailable NPY Y5 receptor antagonists.
Collapse
Affiliation(s)
- Heinrich Rueeger
- Novartis Pharma AG, Novartis Institutes for BioMedical Research Basel, CH-4002 Basel, Switzerland.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Aquino CJ, Ramanjulu JM, Heyer D, Daniels AJ, Palazzo F, Dezube M. Synthesis and structure activity relationship of guanidines as NPY Y5 antagonists. Bioorg Med Chem 2004; 12:2691-708. [PMID: 15110851 DOI: 10.1016/j.bmc.2004.03.012] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2003] [Revised: 02/19/2004] [Accepted: 03/08/2004] [Indexed: 10/26/2022]
Abstract
A series of bis-aryl substituted guanidines have been discovered as potent NPY Y5 antagonists. The SAR and in vitro metabolic stability of these compounds are discussed.
Collapse
|
28
|
Uccello-Barretta G, Balzano F, Sicoli G, Fríglola C, Aldana I, Monge A, Paolino D, Guccione S. Combining NMR and molecular modelling in a drug delivery context: investigation of the multi-mode inclusion of a new NPY-5 antagonist bromobenzenesulfonamide into β-cyclodextrin. Bioorg Med Chem 2004; 12:447-58. [PMID: 14723963 DOI: 10.1016/j.bmc.2003.10.033] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
NMR spectroscopic and molecular modelling methods have been employed to describe the complexation of trans-N-4-[N'-(4-chlorobenzoyl)hydrazinocarbonyl]cyclohexylmethyl-4-bromobenzenesulfonamide, a new chemotype of NPY-5 antagonist, and beta-cyclodextrin, revealing the coexistence of two different kinds of 1:1 complexes where conformational changes of the guest compound with respect to the free state are also detected.
Collapse
Affiliation(s)
- Gloria Uccello-Barretta
- Dipartimento di Chimica e Chimica Industriale, Università degli Studi di Pisa, via Risorgimento 35, 56126 Pisa, Italy.
| | | | | | | | | | | | | | | |
Collapse
|
29
|
Chapter 7. Recent developments in neuropeptide Y receptor modulators. ANNUAL REPORTS IN MEDICINAL CHEMISTRY 2003. [DOI: 10.1016/s0065-7743(03)38008-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register]
|
30
|
Chapter 2. Neuropeptide receptor antagonists for CNS disorders. ANNUAL REPORTS IN MEDICINAL CHEMISTRY 2003. [DOI: 10.1016/s0065-7743(03)38003-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register]
|
31
|
Chapter 24. Obesity therapeutics: Prospects and perspectives. ANNUAL REPORTS IN MEDICINAL CHEMISTRY 2003. [DOI: 10.1016/s0065-7743(03)38025-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register]
|